Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug,...
Affymax (AFFY +8.9%) wins backing from an FDA advisory panel for its peginesatide anemia drug, which competes with a rival drug from Amgen (AMGN). AFFY shares jumped 20%-plus on Monday when briefing documents related to today's meeting were released; trading has been halted since early this afternoon.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at MarketWatch.com (Jun 3, 2013)
at CNBC.com (May 31, 2013)
at MarketWatch.com (Apr 2, 2013)
at MarketWatch.com (Mar 19, 2013)
at CNBC.com (Mar 19, 2013)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs